Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer

Angiogenesis

Volumn 14, Issue 2, 2011, Pages 155-161

  Siddiqui, G K ^a   Maclean, A B ^a   Elmasry, K ^b   Wong Te Fong, A ^a   Morris, R W ^a   Rashid, M ^a   Begent, R H J ^c   Boxer, G M ^c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b TAWAM HOSPITAL   (United Arab Emirates)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chemotherapy; Epithelial ovarian cancer; Immunohistochemistry; Platinum; Resistance; VEGF

Indexed keywords

CARBOPLATIN; PLATINUM COMPLEX; TAXANE DERIVATIVE; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG RESPONSE; DRUG SENSITIVITY; ENDOMETRIOID CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OVARY CANCER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; DEMOGRAPHY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 79959999859     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-010-9199-4     Document Type: Article

References (35)

1. Berek J (2005) Epithelial ovarian cancer. In: Berek J (ed) Practical gynecolgical oncology, vol 4. Lippincott Wiliams and Wilkins, Philadelphia
2. Friedlander ML (1998) Prognostic factors in ovarian cancer. Semin Oncol 25(3):305-314 (Pubitemid 28272604)
3. Duncan TJ, Al-Attar A, Rolland P, Scott IV, Deen S, Liu DT et al (2008) Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 14(10):3030-3035
4. Battegay EJ (1995) Angiogenesis: mechanistic insights, neovas-cular diseases, and therapeutic prospects. J Mol Med 73(7): 333-346
5. Boxer GM, Tsiompanou E, Levine T, Watson R, Begent RH (2005) Immunohistochemical expression of vascular endothelial growth factor and microvessel counting as prognostic indicators in node-negative colorectal cancer. Tumour Biol 26(1):1-8 (Pubitemid 40529292)
6. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1(1):27-31
7. Fujimoto J, Sakaguchi H, Hirose R, Ichigo S, Tamaya T (1998) Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer 83(12): 2528-2533 (Pubitemid 29019573)
8. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR (1992) Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3(2):211-220 (Pubitemid 23084552)
9. Dang DT, Chun SY, Burkitt K, Abe M, Chen S, Havre P et al (2008) Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition. Cancer Res 68(6):1872-1880 (Pubitemid 351416573)
10. Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK et al (2008) Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 13(4):331-342 (Pubitemid 351446192)
11. Neuhaus T, Pabst S, Stier S, Weber AA, Schror K, Sachinidis A et al (2004) Inhibition of the vascular-endothelial growth factor-induced intracellular signaling and mitogenesis of human endothelial cells by epigallocatechin-3 gallate. Eur J Pharmacol 483(2-3):223-227 (Pubitemid 38068403)
12. Mylona E, Nomikos A, Alexandrou P, Giannopoulou I, Keramopoulos A, Nakopoulou L (2007) Lymphatic and blood vessel morphometry in invasive breast carcinomas: relation with proliferation and VEGF-C and -D proteins expression. Histol Histopathol 22(8):825-835 (Pubitemid 47034148)
13. Roberts DL, Williams KJ, Cowen RL, Barathova M, Eustace AJ, Brittain-Dissont S et al (2009) Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. Br J Cancer 101(8):1290-1297
14. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS et al (2006) Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colo-rectal cancer. J Clin Oncol 24(2):217-227 (Pubitemid 46622051)
15. Yamamoto S, Konishi I, Tsuruta Y, Nanbu K, Mandai M, Kuroda H et al (1997) Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. Gynecol Endocrinol 11(6):371-381 (Pubitemid 28029579)
16. Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF et al (1996) Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 74(6):1105-1115 (Pubitemid 26184421)
17. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI et al (2003) Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9(15):5721-5728 (Pubitemid 37499496)
18. Markman M, Hoskins W (1992) Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 10(4):513-514
19. Alvarez AA, Krigman HR, Whitaker RS, Dodge RK, Rodriguez GC (1999) The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 5(3):587-591 (Pubitemid 29131968)
20. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ (1995) Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147(1):33-41
21. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF et al (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80(1):98-106 (Pubitemid 27270925)
22. Gasparini G, Bonoldi E, Viale G, Verderio P, Boracchi P, Panizzoni GA et al (1996) Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 69(3):205-211 (Pubitemid 26233300)
23. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427-434 (Pubitemid 36910021)
24. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12):1539-1544 (Pubitemid 46733080)
25. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF et al (2003) A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30(5 Suppl 16):117-124 (Pubitemid 37433402)
26. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25(33):5180-5186 (Pubitemid 350232248)
27. Folkman J (2004) Endogenous angiogenesis inhibitors. Apmis 112(7-8):496-507 (Pubitemid 39626056)
28. Engels K, du Bois A, Harter P, Fisseler-Eckhoff A, Kommoss F, Stauber R et al (2009) VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection. J Clin Pathol 62(5):448-454
29. Han ES, Monk BJ (2007) Bevacizumab in the treatment of ovarian cancer. Expert Rev Anticancer Ther 7(10):1339-1345 (Pubitemid 351826900)
30. O'Toole SA, Sheppard BL, Laios A, O'Leary JJ, McGuinness EP, D'Arcy T et al (2007) Potential predictors of chemotherapy response in ovarian cancer-how do we define chemosensitivity? Gynecol Oncol 104(2):345-351 (Pubitemid 46135658)
31. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB (2005) Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 11(19 Pt 1):6966-6971 (Pubitemid 41428755)
32. Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O et al (2008) Correlation of NK T-like CD3 + CD56 + cells and CD4 + CD25 + (hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol 108(2):421-427
33. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25(33):5165-5171 (Pubitemid 350237599)
34. Raspollini MR, Amunni G, Villanucci A, Baroni G, Boddi V, Taddei GL (2004) Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 14(5):815-823 (Pubitemid 39238165)
35. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669-676 (Pubitemid 36749215)